NCT00500123 The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
| NCT ID | NCT00500123 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Florida |
| Condition | Alpha-1 Antitrypsin Deficiency |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2001-01 |
| Primary Completion | 2050-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2001-01 with a primary completion date of 2050-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.
Eligibility Criteria
Inclusion Criteria: * Individuals of any age at risk for alpha-1 antitrypsin deficiency on the basis of symptoms or family genetic risk. Exclusion Criteria: * Any person who has already had genotype and AAT level testing completed and has a qualified result.
Contact & Investigator
Karina Serban, M.D.
PRINCIPAL INVESTIGATOR
University of Florida
Frequently Asked Questions
Who can join the NCT00500123 clinical trial?
This trial is open to participants of all sexes, studying Alpha-1 Antitrypsin Deficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00500123 currently recruiting?
Yes, NCT00500123 is actively recruiting participants. Contact the research team at Sandra.Owens@medicine.ufl.edu for enrollment information.
Where is the NCT00500123 trial being conducted?
This trial is being conducted at Gainesville, United States.
Who is sponsoring the NCT00500123 clinical trial?
NCT00500123 is sponsored by University of Florida. The principal investigator is Karina Serban, M.D. at University of Florida. The trial plans to enroll 50,000 participants.